Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 440 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]
2. Cita con resumen
3. Cita con resumen
Rome BN, Avorn J. Drug evaluation during the covid-19 pandemic. N Engl J Med 2020;382:11 de junio. [Ref.ID 103661]
5. Cita con resumen
Lassalle M, Le Tri L, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [Ref.ID 103532]
6. Cita con resumen
7. Cita con resumen
Tracy DK. Gabapentinoids linked to new risks, including suicidal behaviour. BMJ 2019;365:12 de junio. [Ref.ID 103153]
8.Enlace a cita original Cita con resumen
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]
9. Cita con resumen
Thielking M. Federal trial over fentanyl bribes gets underway. STAT Morning Rounds 2019:2. [Ref.ID 103007]
10. Cita con resumen
Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. JAMA 2018;320:27 de noviembre. [Ref.ID 102915]
11.Enlace a cita originalTiene citas relacionadas Cita con resumen
Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, Hall K, Cooper WO. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry 2018:12 de diciembre. [Ref.ID 102895]
12.Enlace a cita original Cita con resumen
Asensio C, Escoda N, Sabaté M, Carbonell P, López P, Laporte JR. Prevalence of use of antipsychotic drugs in the elderly in Catalonia. Eur J Clin Pharmacol 2018;74:septiembre. [Ref.ID 102828]
13.Enlace a cita original Cita con resumen
Cohen LS, Góez-Mogollón L, Sosinsky AZ, Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S, Freeman MP. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry 2018:16 de agosto. [Ref.ID 102798]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wallach JD, Ross JS. Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. JAMA 2018;319:27 de febrero. [Ref.ID 102781]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA 2018;319:27 de febrero. [Ref.ID 102777]
16. Cita con resumen
Thielking M. FDA cracks down on ‘vaginal rejuvenation’ devices, citing potential for serious harm. STAT Daily Recap 2018:30 de julio. [Ref.ID 102728]
18.Enlace a cita original Cita con resumen
Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ, Mogun H, Hyubrechts KF. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ 2018;360:28 de marzo. [Ref.ID 102642]
19.Enlace a cita original Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018;178:febrero. [Ref.ID 102530]
Seleccionar todas
 
 1 a 20 de 440 siguiente >>